Top Clindamycin Brands for Effective Treatments

Clindamycin is an antibiotic commonly used to treat a variety of bacterial infections. Its effectiveness and availability have led to the production of this medication by numerous reputable pharmaceutical brands worldwide. When choosing clindamycin, it's important to consider factors such as brand reliability, availability, and any specific patient needs or allergies. To assist healthcare professionals and patients in making informed decisions, one might explore some of the top brands that produce clindamycin, each known for its quality and efficacy. Discover the leading names in clindamycin production and learn more about their distinguishing features below.

Illustration of clindamycin

Best brands of clindamycin in 2025

Cleocin

Cleocin, a brand of clindamycin hydrochloride, is a leading product in the antibiotic market, known for its effectiveness against serious bacterial infections, including those caused by anaerobic bacteria, streptococci, pneumococci, and staphylococci. The market size for clindamycin hydrochloride is expected to grow from $1.68 billion in 2023 to $2.54 billion by 2028 at a CAGR of 8.6%, driven by factors such as increasing prevalence of bacterial infections and advancements in pharmaceutical formulations. Cleocin is available in various forms, including capsules and intravenous solutions, and has been approved for use for over 40 years. The product is distributed by Pharmacia & Upjohn Co, a division of Pfizer Inc. Its strong growth is also attributed to its use in surgical prophylaxis and the treatment of skin and soft tissue infections. For more information, visit the Cleocin drug information page.

Dalacin

Dalacin, a brand by Pfizer, is renowned for producing high-quality clindamycin, a semi-synthetic antibiotic derived from lincomycin. Clindamycin, available under the Dalacin brand, has a bioavailability of 90% when administered orally and is effective against a range of bacterial infections, including those caused by anaerobic bacteria, gram-positive aerobic bacteria, and Chlamydia trachomatis. It is notable for its substantial plasma protein binding of 95% and an elimination half-life of 2-3 hours. Dalacin C capsules are available in 150 mg and 300 mg strengths and are approved by various regulatory bodies, including the BPOM in Indonesia. Clindamycin has been a crucial medication since its introduction in 1966 and is listed on the World Health Organization's List of Essential Medicines. For more detailed information about Dalacin, you can visit the official Pfizer labeling documentation.

Clindagel

Clindagel, a renowned brand, is a leading producer of clindamycin phosphate gel, specifically formulated for the treatment of acne vulgaris. With a concentration equivalent to 10 mg of clindamycin per gram, Clindagel has demonstrated efficacy in reducing lesion counts by a significant margin in clinical trials, such as a 12-week multicenter study where it showed superior results compared to a vehicle gel. The gel is well-tolerated, though it may cause adverse dermatologic events like burning, itching, and dryness in some patients. Clindamycin phosphate is rapidly hydrolyzed in vivo to the active antibacterial agent clindamycin, which inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Despite its effectiveness, it is contraindicated in individuals with a history of hypersensitivity to clindamycin or antibiotic-associated colitis.

Climadan

Clindamycin, particularly under the brand name Dalacin C by Pfizer, is a highly effective antibiotic produced by one of the leading pharmaceutical companies. It is indicated for the treatment of severe infections caused by susceptible Gram-positive aerobic organisms and anaerobic bacteria, with a high absorption rate of about 90% from the gastrointestinal tract. The drug reaches therapeutic blood concentrations within 45 minutes to 1 hour after oral administration and is widely distributed in body fluids and tissues. Clindamycin is metabolized primarily by the CYP3A4 enzyme and has a half-life of 2 to 3 hours. The market for clindamycin hydrochloride is expected to grow significantly, with a projected market size of $1.82 billion in 2024 and a compound annual growth rate (CAGR) of 8.6% until 2028.

Clinacin

Clindamycin, produced under various brand names including Clindacin, is a highly effective semi-synthetic lincosamide antibiotic used to treat serious infections caused by susceptible anaerobic, streptococcal, staphylococcal, and pneumococcal bacteria. Clindacin formulations, such as solutions, gels, and lotions, are widely used for acne treatment and have a high oral bioavailability of approximately 90%. The drug is rapidly absorbed, reaching peak serum concentrations of 2.50 ug/mL within 45 minutes. Clindamycin is metabolized predominantly by CYP3A4 and has a biological half-life of 2.4 hours. It is available only with a doctor's prescription and is distributed by several pharmaceutical companies, including those offering Clindacin products. For more details about clindamycin, visit the Mayo Clinic's comprehensive guide on clindamycin.

Evoclin

Evoclin, a brand of clindamycin phosphate foam, is a highly effective treatment for acne vulgaris, particularly in patients 12 years and older. It contains 10 mg of clindamycin per gram, formulated in a thermolabile hydroethanolic foam vehicle. In clinical trials, Evoclin Foam demonstrated a treatment response in 31% of patients, with a 49% reduction in inflammatory lesions and a 43% reduction in total lesions. The foam is available in 50 and 100 gram aerosol cans and has shown lower systemic absorption compared to clindamycin gel, with less than 0.024% of the total dose excreted unchanged in the urine over 12 hours.

ClindaMax

ClindaMax, a product of PharmaDerm, is a renowned brand for clindamycin phosphate vaginal cream, specifically indicated for the treatment of bacterial vaginosis. The cream contains 2% clindamycin phosphate, equivalent to 20 mg of clindamycin per gram, and is supplied in a 40 g tube with 7 disposable applicators. It has a pH range of 3.0 to 6.0 and includes ingredients like benzyl alcohol and propylene glycol. ClindaMax vaginal cream is stored at 20° to 25°C (68° to 77°F) and was revised in October 2009. This formulation ensures effective local delivery of clindamycin with minimal systemic absorption.

Clindesse

Clindesse, a renowned brand, offers a highly effective 2% clindamycin phosphate vaginal cream for the treatment of bacterial vaginosis in non-pregnant women. This semi-solid white cream, utilizing proprietary Bioadhesion Technology, reduces leakage by 50% and provides a single-dose treatment option, with medication released at the infection site for multiple days. Clinical studies have shown no significant differences in therapeutic cure rates compared to multi-dose regimens, and 98% of women surveyed reported they would use Clindesse again. The cream contains 100 mg of clindamycin phosphate per 5g applicator and has been studied in diverse patient demographics, including 51% Caucasian, 36% Black, 10% Hispanic, and 3% Asian or other populations. Clindesse has an average user rating of 6.9 out of 10, with 58% of reviewers reporting a positive experience.

Zindaclin

Zindaclin, a renowned brand, is highly regarded for its effective clindamycin phosphate gel, specifically formulated to treat acne by reducing bacterial counts and preventing pore blockage. Each tube of Zindaclin 1% Gel contains 1.2% clindamycin phosphate, equivalent to 1% clindamycin, and is available in 15g or 30g laminate tubes. The product was approved in July 2014 and is manufactured by Dr. August Wolff GmbH & Co. KG, ensuring high-quality standards. Zindaclin does not require special storage conditions and should be used as directed to avoid any adverse effects. It is an essential treatment option for managing acne, particularly effective against *Propionibacterium acnes*.

CLINDET

CLINDETS(r), a product from a reputable manufacturer, is renowned for its effective treatment of moderate acne vulgaris in individuals 13 years and older. It contains clindamycin phosphate, which rapidly hydrolyzes in vivo to the active antibiotic clindamycin, inhibiting bacterial protein synthesis by binding to the 50S subunit of ribosomes. Studies have shown that clindamycin is highly effective against Propionibacterium acnes, with in vitro susceptibility tests indicating that nearly all strains are inhibited at MICs of 0.04 mg/L or less. The topical solution has a low systemic absorption, with less than 0.2% of the dose recovered in urine as clindamycin. This formulation ensures targeted treatment with minimal systemic exposure. For more detailed information, you can visit the official product document.